Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference
Senti Biosciences, Inc. (Nasdaq: SNTI) announced participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 4:05 p.m. ET. Co-founder and CEO Tim Lu, CFO Deb Knobelman, and CMDO Kanya Rajangam will engage in a Fireside Chat during the event. A live webcast will be available on the Senti Bio Investors website for 180 days post-presentation. Senti Bio focuses on next-generation cell and gene therapies using their proprietary gene circuit platform to enhance treatment effectiveness for various diseases, including acute myeloid leukemia.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that co-founder and CEO, Tim Lu, CFO, Deb Knobelman and CMDO, Kanya Rajangam will participate in a Fireside Chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 4:05 p.m. ET.
A live webcast of the Fireside Chat can be accessed under the Events & Presentations section of the Senti Bio Investors website, and will be available for 180 days following the presentation.
About Senti Bio
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. To accomplish this, we are building a synthetic biology platform that may enable us to program next-generation cell and gene therapies with what we refer to as Gene Circuits. These Gene Circuits, which are created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We aim to design Gene Circuits to improve the intelligence of cell and gene therapies in order to enhance their therapeutic effectiveness, precision, and durability against a broad range of diseases that conventional medicines do not readily address.
Our synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuit technologies, to target particularly challenging liquid and solid tumor oncology indications. Our lead development candidate is SENTI-202 for the treatment of acute myeloid leukemia (AML). Additional CAR-NK programs include SENTI-301 for the treatment of hepatocellular carcinoma (HCC) and SENTI-401 for the treatment of colorectal cancer (CRC). We have also demonstrated the breadth of our Gene Circuits in other modalities and diseases outside of oncology and have executed partnerships with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.
Find more information at sentibio.com
Follow us on Linkedin: Senti Biosciences
Follow us on Twitter: @SentiBio
FAQ
What is the date and time of Senti Biosciences' participation in the Morgan Stanley Conference?
Who will represent Senti Biosciences at the Morgan Stanley Conference?
Where can I watch the Senti Biosciences Fireside Chat?
How long will the webcast of the Fireside Chat be available?
What is the focus of Senti Biosciences' gene circuit platform?
What is Senti Biosciences' lead development candidate?
